Table 2 Combination therapeutics based on EPHA2 targeting
Drug | Cancer type | Effects in vitro | Effects in vivo | Ref. |
|---|---|---|---|---|
ALW-II-41-27 + WW437 | Breast cancer | Inhibit cell viability and migration | - | [87] |
ALW-II-41-27 + cetuximab | CRC | Inhibit cell growth, induce apoptosis and cell cycle arrest, revert resistance to cetuximab | Inhibit tumor growth | [27] |
siRNA+ cisplatin/etoposide/minustine hydrochloride | Glioma | Induce cytotoxicity | - | [86] |
UniPR1331 + bevacizumab | Glioblastoma | – | Inhibit tumor growth | [63] |
DS-8895a + cisplatin | Gastric cancer | – | Inhibit tumor growth | [56] |
EphA2-ILs-DTXp + PD-1 inhibitors | Breast cancer (mouse) | – | Inhibit tumor growth | [76] |